Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized multicenter, open label, controlled and non-comparative phase II study of anti-PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung cancer (SCLC)

Next Previous
Trial Profile

A randomized multicenter, open label, controlled and non-comparative phase II study of anti-PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung cancer (SCLC)

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Topotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 18 Jan 2019 Results assessing efficacy of Atezolizumab as Second-Line Therapy in Patients with Small Cell Lung Cancer published in the Journal of Thoracic Oncology
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top